RT Journal Article
SR Electronic
T1 SARS-CoV-2 antibody seroprevalence in cancer patients on systemic antineoplastic treatment in the first wave of the COVID-19 pandemic in Portugal
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.31.22270178
DO 10.1101/2022.01.31.22270178
A1 Fernandes, Gonçalo
A1 Paixão, Paulo
A1 Brum, Laura
A1 Padrão, Teresa
A1 Correia, Jorge
A1 Albuquerque, Joana
A1 Pulido, Catarina
A1 Nave, Mónica
A1 Timóteo, Teresa
A1 Rodrigues, Tânia
A1 Costa, Filipe
A1 Passos Coelho, José Luís
YR 2022
UL http://medrxiv.org/content/early/2022/02/02/2022.01.31.22270178.abstract
AB At the time of the first wave of the COVID-19 pandemic cancer patients were considered to be at high risk of serious illness and had a higher exposure risk since they needed frequent and non- deferrable hospital visits. Serologic tests were not routinely used and seroprevalence in this population was unknown.A single-center cross-sectional study was developed to determine the seroprevalence of anti- SARS-CoV-2 antibodies (Abs) in cancer patients undergoing systemic antineoplastic treatment. One hundred patients were consecutively recruited in a two-week period (6th to 20th May, 2020) and serum samples were tested for the presence of IgM and IgG Abs directed against both spike and nucleocapsid SARS-CoV-2 proteins in two distinct timepoints (at recruitment and four to eight weeks later). IgG positive results were subject to confirmation, in the same serum sample, using two distinct assays.At the time of the first study visit, no patient had a previously confirmed diagnosis of COVID-19, one reported previous contact with a COVID-19 patient and all had a baseline SARS-CoV-2 negative RT-PCR. Two patients tested positive for SARS-CoV-2 IgG in the first study visit, which was not confirmed in either of the two confirmatory assays. Seventy-two patients were tested at the second study visit, all with negative IgG test. IgM was persistently positive at both study visits in one patient and was positive in another patient at the second study visit, both with negative RT-PCR and serum IgG. No patient tested RT-PCR positive within the study timeframe.No evidence of prior or acute SARS-CoV-2 infection was documented in this cohort of cancer patients undergoing systemic treatment and no additional exposure risk was documented compared to general population seroprevalence studies. The study was inconclusive regarding the role of SARS-CoV-2 serology in cancer patients in the early phase of the pandemic. This study did show that, with adherence to recommended preventive measures, it was safe to maintain systemic cancer therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financially supported by Novartis Oncology Portugal (Investigator Initiated Trial CINC424A0PT01T).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Hospital da Luz Lisboa gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.